MDA - Market Direction Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis

SPY 684.84

+0.6%

4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: HairBall who wrote (1077)	12/9/1998 6:55:00 PM
From: HammerHead	Read Replies (1) of 99985

from briefing.com Merck & Co. (MRK) 151 15/16 -5 3/4: pharmaceutical concern says that it expects FY98 EPS between $4.27 and $4.34 a share, in line with the First Call estimate of $4.30, but sees FY99 between $4.85 and $.95 a share, below the First Call mean estimate of $4.97 a share; company also reports two six-month safety studies on VIOXX, its once-daily, anti-inflammatory COX-2 specific inhibitor, the cumulative rate of ulcers was similar to the rate on placebo and significantly less than the rate on ibuprofen; with regards to two acute pain studies, VIOXX relieved dental pain and post-orthopedic surgery pain comparable to widely used prescription NSAIDs and superior to placebo.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next